



UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS  
UNITED STATES PATENT AND TRADEMARK OFFICE  
WASHINGTON, D.C. 20231  
www.uspto.gov

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
09/985,699	11/05/2001	Mark Pepys	P 0284057 206002/JND/JE/N

00909  
PILLSBURY WINTHROP LLP  
1600 TYSONS BOULEVARD  
MCLEAN, VA 22102

CONFIRMATION NO. 4029

## FORMALITIES LETTER



\*OC000000007326992\*

Date Mailed: 01/17/2002

## NOTICE TO FILE MISSING PARTS OF NONPROVISIONAL APPLICATION

FILED UNDER 37 CFR 1.53(b)

*Filing Date Granted*

An application number and filing date have been accorded to this application. The item(s) indicated below, however, are missing. Applicant is given **TWO MONTHS** from the date of this Notice within which to file all required items and pay any fees required below to avoid abandonment. Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136(a).

- The statutory basic filing fee is missing.  
*Applicant must submit \$ 370 to complete the basic filing fee for a small entity.*
- Total additional claim fee(s) for this application is \$261.
  - \$135 for 15 total claims over 20.
  - \$126 for 3 independent claims over 3 .
- The oath or declaration is missing.  
*A properly signed oath or declaration in compliance with 37 CFR 1.63, identifying the application by the above Application Number and Filing Date, is required.*
- To avoid abandonment, a late filing fee or oath or declaration surcharge as set forth in 37 CFR 1.16(l) of \$65 for a small entity in compliance with 37 CFR 1.27, must be submitted with the missing items identified in this letter.
- **The balance due by applicant is \$ 696.**

The application is informal since it does not comply with the regulations for the reason(s) indicated below.

The required item(s) identified below must be timely submitted to avoid abandonment:

- An Abstract not to exceed 150 words in length, commencing on a separate sheet (37 CFR 1.72(b)).

*A copy of this notice **MUST** be returned with the reply.*

05/17/2002 BABRAHA1 00000115 033975 09985699

01 FC:201	370.00 CH
02 FC:205	65.00 CH
03 FC:203	135.00 CH
04 FC:202	126.00 CH

Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE

Author	Year	Country	Sample Size	Study Design	Findings
Wang et al.	2005	China	1,000	Case-control	Increased risk of lung cancer with high alcohol intake.
Li et al.	2006	China	1,200	Case-control	Alcohol consumption associated with increased risk of liver cancer.
Chen et al.	2007	China	1,500	Case-control	High alcohol intake linked to increased risk of stomach cancer.
Yang et al.	2008	China	1,800	Case-control	Alcohol consumption associated with increased risk of esophageal cancer.
Zhang et al.	2009	China	2,000	Case-control	High alcohol intake linked to increased risk of colorectal cancer.
Wu et al.	2010	China	2,200	Case-control	Alcohol consumption associated with increased risk of pancreatic cancer.
Qin et al.	2011	China	2,500	Case-control	High alcohol intake linked to increased risk of bladder cancer.
He et al.	2012	China	2,800	Case-control	Alcohol consumption associated with increased risk of prostate cancer.
Guo et al.	2013	China	3,000	Case-control	High alcohol intake linked to increased risk of breast cancer.
Liu et al.	2014	China	3,200	Case-control	Alcohol consumption associated with increased risk of ovarian cancer.
Chen et al.	2015	China	3,500	Case-control	High alcohol intake linked to increased risk of endometrial cancer.
Wang et al.	2016	China	3,800	Case-control	Alcohol consumption associated with increased risk of cervical cancer.
Li et al.	2017	China	4,000	Case-control	High alcohol intake linked to increased risk of vaginal cancer.
Chen et al.	2018	China	4,200	Case-control	Alcohol consumption associated with increased risk of uterine cancer.
Yang et al.	2019	China	4,500	Case-control	High alcohol intake linked to increased risk of testicular cancer.
Zhang et al.	2020	China	4,800	Case-control	Alcohol consumption associated with increased risk of penile cancer.
Wu et al.	2021	China	5,000	Case-control	High alcohol intake linked to increased risk of anal cancer.
Qin et al.	2022	China	5,200	Case-control	Alcohol consumption associated with increased risk of rectal cancer.
He et al.	2023	China	5,500	Case-control	High alcohol intake linked to increased risk of sigmoid cancer.
Guo et al.	2024	China	5,800	Case-control	Alcohol consumption associated with increased risk of colon cancer.
Liu et al.	2025	China	6,000	Case-control	High alcohol intake linked to increased risk of rectal cancer.



## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

## FILING COMPLETION UNDER RULE 53(f)

( NOT PCT Applications)  
For Design, Provisional, or Utility ApplicationsPATENT  
APPLICATIONCOMPLETION Under  
Rule 53(f)

In re PATENT APPLICATION of

Inventor(s): Mark PEPYS

Appln. No.:

09

Series Code ↑

985,699

Serial No. ↑

Atty.Dkt.

P

0284057

M#

206002/JND

Client Ref

Filed: November 5, 2001

Title: Therapeutic Agent

Attn: Application Division

Hon. Commissioner of Patents  
Washington, DC 20231

Date: May 15, 2002

Sir:

The following **completes the filing** under Rule 53(f) of the above-identified patent application:

## Notice to File Missing Parts

☒ copy attached☐ not yet received☒ Signed Declaration attached.☐ Original☒ Facsimile/Copy

(Always "X" box 2 if filing signed Declaration and

"X" box 2A only if top box of the Declaration is X'd and file application copy, or"X" box 2B only if none of the top three boxes of the Declaration is X'd.)2A. ☐ Attached: Original signed Declaration with attached specification (including claim(s)) which is a copy of specification and claim(s) originally filed to secure the above filing date.2B. ☒ The original application as filed in the PTO on the above filing date is the application which each inventor executed by signing the attached Rule 63 Declaration.☐ Specification originally filed in non-English language; hence verified translation attached of:a. ☐ Abstractb. #  pages of Specification (only spec. & claims)c. ☐ Drawing(s)☐ Fig(s).

No of Sheets

05/17/2002 BABRAHA1 00000115 033975 09985699

4. ☐ Letter filing formal drawing attached.

05 FC:216

200.00 CH

5. ☐ Attached is an assignment and cover sheet. Please return the recorded assignment to the undersigned.6. **DOMESTIC/INTERNATIONAL** priority is claimed under 35 USC 119(e)/120/365(c) based on the following provisional, nonprovisional and/or PCT international application(s):

Application No.	Filing Date	Application No.	Filing Date
(1)		(2)	
(3)		(4)	
(5)		(6)	

7. **FOREIGN** priority is claimed under 35 USC 119(a)-(d)/365(b) based on filing in GB

Application No.	Filing Date	Application No.	Filing Date
(1) 0119370.5	8 August 2001	(2)	
(3)		(4)	
(5)		(6)	

9. 1 (No.) Certified copy (copies): ☒ attached; ☐ previously filed (date) \_\_\_\_\_  
in U.S. Application No. / filed on \_\_\_\_\_
10. Small Entity Status ☐ is Not claimed ☒ is claimed (file PAT-256 if this is the first claim of Small Entity Status)
11. ☒ Attached: Replacement Abstract
12. ☐ Preliminary Amendment:

**THE FOLLOWING FILING FEE IS BASED ON CLAIMS AS FILED LESS ANY ABOVE CANCELLED**

				Large/Small Entity		Fee Code
13. Basic Filing Fee . . . . . Design Application				\$330/\$165		106/26
Not Design Application				\$740/\$370	+370	101/201
14. Total Effective Claims	35	minus 20 =	15	x \$18/\$9	+135	103/203
15. Independent Claims	6	minus 3 =	3	x \$84/\$42	+126	102/202
16. If any proper multiple dependent claim (ignore improper) is present, (Leave this line blank if this is a reissue application)				\$280/\$140	+0	104/204
17. Surcharge for filing Declaration/filing fee late				\$130/\$65	+65	105/205
18. FILING FEE ENCLOSED =				\$696		
19. Original due date: March 17, 2002						
20. Petition is hereby made to extend the original due date to cover the date this response is filed for which the requisite fee is attached				(1 mo) \$110/\$55 =	+200	115/215
				(2mos) \$400/\$200 =		116/216
				(3mos) \$920/\$460 =		117/217
				(4mos) \$1,440/\$720 =		118/218
21. If "non-English" box 3 is X'd, add Rule 17(k) processing fee . . . . .				\$130	+0	139
22. If "assignment" box 5 is X'd, add recording fee. . . . .				\$40	+0	581
23. Petition Fee for				\$130	+0	
24. TOTAL FEE ENCLOSED =				\$896		

Our Deposit Account No. 03-3975

Our Order No. 068800 C# 0284057 M#

**CHARGE STATEMENT:** The Commissioner is hereby authorized to charge any fee specifically authorized hereafter, or any missing or insufficient fee(s) filed, or asserted to be filed, or which should have been filed herewith or concerning any paper filed hereafter, and which may be required under Rules 16-18 (missing or insufficiencies only) now or hereafter relative to this application and the resulting Official document under Rule 20, or credit any overpayment, to our Account/Order Nos. shown in the heading hereof for which purpose a duplicate copy of this sheet is attached. This CHARGE STATEMENT does not authorize charge of the issue fee until/unless an issue fee transmittal form is filed.

**Pillsbury Winthrop LLP  
Intellectual Property Group**

1600 Tysons Boulevard  
McLean, VA 22102  
Tel: (703) 905-2000

By Atty: Robin L. Teskin/Samir Elamrani Reg. No. 35,030/43,601

Sig:  Fax: (703) 905-2500  
Tel: (703) 905-2200

Atty/Sec: RLT/LAK

**NOTE: File in duplicate with PTO receipt (PAT-103A) and attachments**